|
Effects of Drugs on Cerebral Blood Flow in Patients with Mood Disorders Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on Effects of Drugs on Cerebral Blood Flow in Patients with Mood Disorders conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Effects of Drugs on Cerebral Blood Flow in Patients with Mood Disorders Clinical research trials and Effects of Drugs on Cerebral Blood Flow in Patients with Mood Disorders medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like Effects of Drugs on Cerebral Blood Flow in Patients with Mood Disorders. Effects of Drugs on Cerebral Blood Flow in Patients with Mood Disorders Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a Effects of Drugs on Cerebral Blood Flow in Patients with Mood Disorders clinical trial. Participants frequently obtain the most expert healthcare available for their Effects of Drugs on Cerebral Blood Flow in Patients with Mood Disorders condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Effects of Drugs on Cerebral Blood Flow in Patients with Mood Disorders  Effects of Drugs on Cerebral Blood Flow in Patients with Mood Disorders
Effects of Drugs on Cerebral Blood Flow in Patients with Mood Disorders
For Condition: Healthy,Mood Disorders
Status: Completed
Sponsor(s): National Institute of Mental Health (NIMH) ,
Synopsis: Positron Emission Tomography (PET) is a technique used to investigate the functional activity of the brain. The PET technique allows doctors to study the normal biochemical and metabolic processes of the central nervous system of normal individuals and patients with neurologic illnesses without physical / structural damage to the brain. When a region of the brain is active, it uses more fuel in the form of oxygen and sugar (glucose). As the brain uses more fuel it produces more waste products, carbon dioxide and water. Blood carries fuel to the brain and waste products away from the brain. As brain activity increases blood flow to and from the area of activity increases also. Knowing these facts, researchers can use radioactive chemicals (H215O) and PET scans to observe what areas of the brain are receiving more blood flow. Patients diagnosed with mood disorders and healthy volunteers will receive positron emission tomographic (PET) scans with H215O while doing simple tasks. Patients will continue to receive scans while in different mood states and while taking different medications. Patients eligible for this study will be participating in other research studies measuring other clinical and biochemical parameters (mood and anxiety ratings, medication responses, and psychological test results). Information gathered from H215O PET scans measuring blood flow to specific brain areas will be compared to the data gathered from other studies. Objectives of this study are; 1. To determine differences in blood flow to the brain of patients with mood disorders compared to healthy volunteers. 2. To determine differences in blood flow to the brain of patients with subtype mood disorders (such as unipolar versus bipolar) compared to healthy volunteers. 2. To determine changes in blood flow to the brain of patients with mood disorders who experience spontaneous changes in symptoms 3. To determine changes in blood flow to the brain of patients with mood disorders who receive various kinds of therapy (medication, transcranial magnetic stimulation, etc.) 4. To determine if blood flow to specific areas of the brain can be used to predict how patients will respond to certain types of therapy 5. To compare blood flow changes with various other clinical and biochemical parameters.
Details: Patients with mood disorders and healthy volunteers will receive positron emission tomographic (PET) scans with H(2)(15)O to measure global and local differences in cerebral blood flow during a passive introspection task. Patients receive repeated scans while in different mood states and while participating in placebo controlled therapeutic trials as described by separate protocols. Global and regional cerebral blood flow is correlated with data obtained from participation in other protocols, which include clinical (life charting course of illness parameters, mood and anxiety ratings, medication response data, and psychological test performance) and biochemical (levels of medications, monoamines and peptides in the blood and cerebrospinal fluid) measures.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Healthy volunteers and patients who satisfy DSM-III-R criteria for mood disorders between ages of 18 and 75 will be invited to participate provided that the following criteria are fulfilled: No history of medical illness (including seizures, endocrine, hepatic, renal, cardiac, allergic, infectious, autoimmune, or neurological disorders) that would contraindicate participation. No evidence of co-existing major illness after undergoing complete psychiatric (including SADS-LA interview), medical, neurological, and laboratory examinations (including EEG, EKG, renal and liver function tests, serum electrolytes, urinalysis, HIV, hepatitis B, syphilis). Negative pregnancy test for women of child bearing potential. Women must not be breast feeding. Negative HIV test, as we are studying primary mood and anxiety disorders and not disorders secondary to HIV infection. Negative urine comprehensive drug screen and have not had alcohol or substance abuse problems in last 12 months.
Total Enrollment: 170
Location and Contact Information:
National Institute of Mental Health (NIMH)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 950016; 95-M-0016
Study Start Date: October 22, 1994
Record last reviewed: January 18, 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001478
Other Mood Disorders Studies:
1. Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients with Thyroid or Pituitary Abnormalities
2. Lipoprotein Metabolism in Normal Volunteers and Patients with High Levels of Lipoproteins
3. MRI Language Studies in Young Children
4. PET Imaging of DHA Metabolism
5. Dynamic Light Scattering Device (DLS) Study of Age-Related Changes in the Lens and Cataracts
Related Studies:
Other Mood Disorders Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Effects of Drugs on Cerebral Blood Flow in Patients with Mood Disorders
|
|
|
|
|
|
|
|
